Literature DB >> 22157287

Prognostic determinants in prostate cancer.

Neil E Martin1, Lorelei A Mucci, Massimo Loda, Ronald A Depinho.   

Abstract

Clinical outcomes in prostate cancer are heterogeneous, and given the high prevalence of the disease, there is a pressing need to identify clinically useful markers of prognosis. Many clinical, pathological, molecular, and genetic factors have been investigated in this capacity, although relatively few are routinely used. With a growing understanding of the molecular pathogenesis of prostate cancer, there is the potential that the next generation of makers will prove sufficiently robust to guide the optimal management of men with prostate cancer. Here, we review the various clinical and molecular prognostic determinants in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22157287      PMCID: PMC3240856          DOI: 10.1097/PPO.0b013e31823b042c

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  112 in total

1.  Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

Authors:  Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone
Journal:  Lancet Oncol       Date:  2011-03       Impact factor: 41.316

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.

Authors:  Shannon L Stott; Richard J Lee; Sunitha Nagrath; Min Yu; David T Miyamoto; Lindsey Ulkus; Elizabeth J Inserra; Matthew Ulman; Simeon Springer; Zev Nakamura; Alessandra L Moore; Dina I Tsukrov; Maria E Kempner; Douglas M Dahl; Chin-Lee Wu; A John Iafrate; Matthew R Smith; Ronald G Tompkins; Lecia V Sequist; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran
Journal:  Sci Transl Med       Date:  2010-03-31       Impact factor: 17.956

4.  Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival.

Authors:  D P Wood; M Banerjee
Journal:  J Clin Oncol       Date:  1997-12       Impact factor: 44.544

5.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

6.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

Review 7.  Urinary prostate cancer 3 test: toward the age of reason?

Authors:  Virginie Vlaeminck-Guillem; Alain Ruffion; Jean André; Marian Devonec; Philippe Paparel
Journal:  Urology       Date:  2009-07-08       Impact factor: 2.649

8.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

Authors:  A W Partin; S Piantadosi; M G Sanda; J I Epstein; F F Marshall; J L Mohler; C B Brendler; P C Walsh; J W Simons
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  21 in total

1.  CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer.

Authors:  Manisha Agarwal; Chang He; Javed Siddiqui; John T Wei; Jill A Macoska
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

Review 2.  The roots of cancer: stem cells and the basis for tumor heterogeneity.

Authors:  Maho Shibata; Michael M Shen
Journal:  Bioessays       Date:  2012-10-02       Impact factor: 4.345

3.  Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.

Authors:  Sungyong You; Beatrice S Knudsen; Nicholas Erho; Mohammed Alshalalfa; Mandeep Takhar; Hussam Al-Deen Ashab; Elai Davicioni; R Jeffrey Karnes; Eric A Klein; Robert B Den; Ashley E Ross; Edward M Schaeffer; Isla P Garraway; Jayoung Kim; Michael R Freeman
Journal:  Cancer Res       Date:  2016-06-14       Impact factor: 12.701

4.  Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score.

Authors:  David Albala; Michael J Kemeter; Phillip G Febbo; Ruixiao Lu; Vincy John; Dylan Stoy; Bela Denes; Marybeth McCall; Alan W Shindel; Frank Dubeck
Journal:  Rev Urol       Date:  2016

5.  Development and testing quantitative metrics from multi-parametric magnetic resonance imaging that predict Gleason score for prostate tumors.

Authors:  Rulon Mayer; Charles B Simone; Baris Turkbey; Peter Choyke
Journal:  Quant Imaging Med Surg       Date:  2022-03

6.  Combining and analyzing novel multi-parametric magnetic resonance imaging metrics for predicting Gleason score.

Authors:  Rulon Mayer; Baris Turkbey; Peter Choyke; Charles B Simone
Journal:  Quant Imaging Med Surg       Date:  2022-07

7.  Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.

Authors:  Xiaoming Ju; Mathew C Casimiro; Michael Gormley; Hui Meng; Xuanmao Jiao; Sanjay Katiyar; Marco Crosariol; Ke Chen; Min Wang; Andrew A Quong; Michael P Lisanti; Adam Ertel; Richard G Pestell
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

8.  Biomarkers to guide therapy or surveillance for prostate cancer.

Authors:  Deborah Citrin; Kathryn Hudak; Kevin A Camphausen
Journal:  Biomark Med       Date:  2013-12       Impact factor: 2.851

9.  Prostate tumor eccentricity predicts Gleason score better than prostate tumor volume.

Authors:  Rulon Mayer; Charles B Simone; Baris Turkbey; Peter Choyke
Journal:  Quant Imaging Med Surg       Date:  2022-02

10.  High incidence of prostate cancer metastasis in Afro-Brazilian men with low educational levels: a retrospective observational study.

Authors:  Alexandre Barbosa Câmara de Souza; Hugo Gonçalo Guedes; Victor Carbone Bernardes Oliveira; Fábio Aires de Araújo; Carlos Cesar Oliveira Ramos; Karina Carla Paula Medeiros; Raimundo Fernandes Araújo
Journal:  BMC Public Health       Date:  2013-06-04       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.